Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals

Natasha K. Martin; Peter Vickerman; Jason Grebely; Margaret Hellard; Sharon J. Hutchinson; Viviane D. Lima; Graham R. Foster; John F. Dillon; David J. Goldberg; Gregory J. Dore; Matthew Hickman

doi:10.1002/hep.26431

Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals

Natasha K. Martin, Peter Vickerman, Jason Grebely, Margaret Hellard, Sharon J. Hutchinson, Viviane D. Lima, Graham R. Foster, John F. Dillon, David J. Goldberg, Gregory J. Dore, Matthew Hickman

SHLS School Office

Research output: Contribution to journal › Article

112 Downloads (Pure)

Abstract

Substantial reductions in hepatitis C virus (HCV) prevalence among people who inject drugs (PWID) cannot be achieved by harm reduction interventions such as needle exchange and opiate substitution therapy (OST) alone. Current HCV treatment is arduous and uptake is low, but new highly effective and tolerable interferon-free direct-acting antiviral (DAA) treatments could facilitate increased uptake. We projected the potential impact of DAA treatments on PWID HCV prevalence in three settings.

Original language	English
Pages (from-to)	1598–1609
Number of pages	12
Journal	Hepatology
Volume	58
Issue number	5
Early online date	26 Aug 2013
DOIs	https://doi.org/10.1002/hep.26431
Publication status	Published - Nov 2013

Fingerprint

Keywords

hepatitis C
antiviral treatment
intravenous drug users

Cite this

Martin, N. K., Vickerman, P., Grebely, J., Hellard, M., Hutchinson, S. J., Lima, V. D., Foster, G. R., Dillon, J. F., Goldberg, D. J., Dore, G. J., & Hickman, M. (2013). Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals. Hepatology, 58(5), 1598–1609. https://doi.org/10.1002/hep.26431

Martin, Natasha K. ; Vickerman, Peter ; Grebely, Jason ; Hellard, Margaret ; Hutchinson, Sharon J. ; Lima, Viviane D. ; Foster, Graham R. ; Dillon, John F. ; Goldberg, David J. ; Dore, Gregory J. ; Hickman, Matthew. / Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals. In: Hepatology. 2013 ; Vol. 58, No. 5. pp. 1598–1609.

@article{be80a90c0fd444a3a1cfea67e1fe68b1,

title = "Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals",

abstract = "Substantial reductions in hepatitis C virus (HCV) prevalence among people who inject drugs (PWID) cannot be achieved by harm reduction interventions such as needle exchange and opiate substitution therapy (OST) alone. Current HCV treatment is arduous and uptake is low, but new highly effective and tolerable interferon-free direct-acting antiviral (DAA) treatments could facilitate increased uptake. We projected the potential impact of DAA treatments on PWID HCV prevalence in three settings. ",

keywords = "hepatitis C, antiviral treatment, intravenous drug users",

author = "Martin, {Natasha K.} and Peter Vickerman and Jason Grebely and Margaret Hellard and Hutchinson, {Sharon J.} and Lima, {Viviane D.} and Foster, {Graham R.} and Dillon, {John F.} and Goldberg, {David J.} and Dore, {Gregory J.} and Matthew Hickman",

note = "Copyright VC 2013 The Authors. Hepatology published by Wiley on behalf of the American Association for the Study of Liver Diseases. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. View this article online at wileyonlinelibrary.com. DOI 10.1002/hep.26431",

year = "2013",

month = nov

doi = "10.1002/hep.26431",

language = "English",

volume = "58",

pages = "1598–1609",

journal = "Hepatology",

issn = "0270-9139",

publisher = "John Wiley and Sons Ltd",

number = "5",

}

Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals. / Martin, Natasha K.; Vickerman, Peter; Grebely, Jason; Hellard, Margaret; Hutchinson, Sharon J.; Lima, Viviane D.; Foster, Graham R.; Dillon, John F.; Goldberg, David J.; Dore, Gregory J.; Hickman, Matthew.

In: Hepatology, Vol. 58, No. 5, 11.2013, p. 1598–1609.

Research output: Contribution to journal › Article

TY - JOUR

T1 - Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals

AU - Martin, Natasha K.

AU - Vickerman, Peter

AU - Grebely, Jason

AU - Hellard, Margaret

AU - Hutchinson, Sharon J.

AU - Lima, Viviane D.

AU - Foster, Graham R.

AU - Dillon, John F.

AU - Goldberg, David J.

AU - Dore, Gregory J.

AU - Hickman, Matthew

N1 - Copyright VC 2013 The Authors. Hepatology published by Wiley on behalf of the American Association for the Study of Liver Diseases. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. View this article online at wileyonlinelibrary.com. DOI 10.1002/hep.26431

PY - 2013/11

Y1 - 2013/11

N2 - Substantial reductions in hepatitis C virus (HCV) prevalence among people who inject drugs (PWID) cannot be achieved by harm reduction interventions such as needle exchange and opiate substitution therapy (OST) alone. Current HCV treatment is arduous and uptake is low, but new highly effective and tolerable interferon-free direct-acting antiviral (DAA) treatments could facilitate increased uptake. We projected the potential impact of DAA treatments on PWID HCV prevalence in three settings.

AB - Substantial reductions in hepatitis C virus (HCV) prevalence among people who inject drugs (PWID) cannot be achieved by harm reduction interventions such as needle exchange and opiate substitution therapy (OST) alone. Current HCV treatment is arduous and uptake is low, but new highly effective and tolerable interferon-free direct-acting antiviral (DAA) treatments could facilitate increased uptake. We projected the potential impact of DAA treatments on PWID HCV prevalence in three settings.

KW - hepatitis C

KW - antiviral treatment

KW - intravenous drug users

UR - http://www.scopus.com/inward/record.url?scp=84878300065&partnerID=8YFLogxK

U2 - 10.1002/hep.26431

DO - 10.1002/hep.26431

M3 - Article

AN - SCOPUS:84878300065

VL - 58

SP - 1598

EP - 1609

JO - Hepatology

JF - Hepatology

SN - 0270-9139

IS - 5

ER -

Documents and Links

10.1002/hep.26431

Martin, N.K et al (2013) Hepatology journal article
Copyright 2013 The Authors. Hepatology published by Wiley on behalf of the American Association for the Study of Liver Diseases. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. View this article online at the DOI link below.
Final published version, 677 KB

Link to publication in Scopus